Pacific Edge Limited posts $7.1 million revenue and $19.1 million net loss for first half 2026

Reuters11-25
<a href="https://laohu8.com/S/PFGTF">Pacific Edge Limited</a> posts $7.1 million revenue and $19.1 million net loss for first half 2026

Pacific Edge Limited reported total revenue of $7.1 million for the first half of fiscal year 2026, a decrease of 42.8% compared to the second half of 2025. Test volumes totaled 13,191 globally, down 10.1% from the previous period, with US total tests at 10,693 (down 13.1%) and APAC total tests at 2,498 (up 5.4%). Commercial test volumes declined 15.9% to 10,371. Net loss after tax was $19.1 million, compared to a net loss of $15.4 million in the previous half. Cash and cash equivalents stood at $22.1 million. The company maintained its US market presence following a loss of coverage and noted ongoing efforts related to Medicare appeals and re-coverage. Pacific Edge is also considering capital initiatives to address a longer-than-expected Medicare re-coverage timeline and highlighted a draft CMS pricing for its Triage Plus test at $1,328 per test.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Edge Limited published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment